ColoAlert | Cancer Screening
ColoAlert | Cancer Screening
Impossible de charger la disponibilité du service de retrait
 This product is available only for Italy, United Arab Emirates and Ireland
|
ColoAlert is a CE-IVD marked, non-invasive and specific colorectal cancer screening test.
- Sensitivity of 85%, even in the early stages of tumor development 1
- Effective even in the absence of blood loss in the stool
- Non-invasive, painless and fast (takes less than 5 minutes)
- 60% more cases detected than occult blood testing (FIT) 1, 2
This test can check for possible colorectal cancer at any stage of development, with a completely painless sample collection method.
Early diagnosis plays a crucial role in the success of therapies, but obtaining it is not easy as the symptoms of the tumor are silent in the early stages of development.
Make your prevention plan efficient, sustainable and timely with ColoAlert
1) Dollinger MM et al. (2018), ClinLab 64(10), 1719-1730.
2) Gies et al. (2018). Gastroenterology 154(1), 93-104. 3) Cooper GS et al. (2018). Dig Dis Sci. 63(6), 1449-1453.
Une technologie de pointe
Une technologie de pointe
Grâce à une analyse de l'ADN, ce test est capable de reconnaître à la fois la partie du code génétique humain et celle d'une masse tumorale. De cette façon, le laboratoire est en mesure de vérifier la présence de la tumeur dans toutes ses phases, à partir du seul échantillon de selles.
Vie privée et sécurité
Vie privée et sécurité
Conforme à la réglementation européenne en matière de sécurité et de confidentialité (GDPR).
Livraison gratuite
Livraison gratuite
Frais d'expédition gratuits tant pour la réception du kit de collecte que pour l'envoi de l'échantillon au laboratoire.
Collecte d'échantillons sans douleur
Collecte d'échantillons sans douleur
Pour effectuer le test, vous devez prélever un échantillon de selles. Le processus est simple, non invasif et ne prend pas plus de 5 minutes.
Next Generation Screening
-
3 years of coverage
-
85% Sensitivity *
-
92% Specificity **
-
Painless and Non Invasive
-
Early Detection
-
+60% efficiency compared to FIT
* Sensitivity, ability to correctly identify cases of patients actually suffering from the disease
** Specificity, ability to correctly identify cases of patients not affected by the disease
Comment cela fonctionne-t-il ?
-
Achetez et recevez le test dans le confort de votre maison.
Free shipping and sending the sample to the lab
-
Envoyez gratuitement l'échantillon au laboratoire
Keep your data in order and secure in your personal account
-
Recevez les résultats dans les jours qui suivent la réception
Receive the digital panels signed and commented by the doctor
Le véritable danger du cancer colorectal
About 70% of colon cancer cases affect people over the age of 50.
For those over 50 and for those with a family history of colorectal cancer, it is therefore strongly recommended to follow a constant screening plan and not wait for symptoms to appear.
Signs such as blood loss in the stool are found mainly in the third and fourth stages of tumor development - the penultimate and last, respectively. In these phases the tumor mass is so extensive that it is damaged by the passage of stools along the intestine, for this reason it is damaged and releases traces of blood.
Waiting for obvious symptoms to appear has a strong impact not only on the cost of therapies, but also on their chances of success, which are much lower in the last two stages of tumor development than in cases of timely diagnosis.
ColoAlert and FIT
The fecal immunochemical test (FIT) detects the presence of polyps in the intestinal tract that have grown to a cancerous state. These polyps reach such a voluminous mass that they are damaged when the stool passes through the intestine, releasing traces of blood.
The presence of traces of blood in the stool due to a polyp, therefore, depends on an advanced degree of development of the tumor mass. Furthermore, we must not forget that other problems, unrelated to the presence of a tumor, can also lead to blood loss of this type. Let's think, for example, of intestinal ulcers, hemorrhoids, diverticulosis and more.
To overcome all these constraints, ColoAlert has been designed with a double analysis:
-
Fecal Occult Blood Test GOLD
Next Generation version GOLD
to detect the presence of hemoglobin, and consequently blood, in the stools.
-
DNA Test
Real Time PCR technology
Genetic analysis to detect tumor markers and the quantification of human DNA.
The identification of multiple risk factors allows ColoAlert to overcome the limits connected not only to blood traces dispersed in the stools, but also to all those symptoms that can be confused with other non-pathological problems or problems that cannot be found in the early stages of tumor development.
ColoAlert and Colonoscopy
The diagnostic test for identifying colorectal cancer is colonoscopy.
This exam allows you to receive a real-time picture of the clinical state of the colorectum. Despite the various advantages conferred by this examination, many patients are reluctant to undergo it and it is not chosen for a constant prevention strategy.
The main frictions are related to the preoperative diet and the degree of invasiveness and pain of the type of exam. Many gastroenterologists declare that a percentage of patients avoid undergoing colonoscopy even if prescribed by the doctor and already booked.
In these cases ColoAlert helps to create a sustainable, non-invasive and painless screening strategy, which patients can follow even in the long term without particular efforts.
It also allows, with a sensitivity of 85% and a specificity of 92%, to achieve an efficacy such as to recommend colonoscopy in cases where it is really required, as well as giving a strong motivation to those patients who are undecided about colonoscopy.
Genetic Analysis reveals:
-
Human DNA (hDNA)
The above-threshold amount of human DNA in stools indicates an intensive proliferation of cells. This factor can be associated with a strong inflammation or to the development of polyps / tumoral mass.
-
Biomarker KRAS
KRAS gene mutations are present in approximately 25% of cancers, particularly 40% of colorectal cancer cases.
This makes these genetic mutations one of the most linked to cancer.
-
Biomarker BRAF
BRAF gene mutations are present in about 10% of colorectal cancer. In these cases it is possible that the tumor is of a rare type, resistant to traditional therapies, which makes timely detection even more important.
L'unicité du test Coloalert
Détection précoce
Le test ColoAlert identifie un cancer potentiel même en l'absence de symptômes évidents ou de présence de sang occulte dans les selles. Il est donc efficace à tous les stades de développement de la maladie.
100% sans douleur
Pratique et simple, avec deux dispositifs : un écouvillon et un flacon pour recueillir les deux échantillons de selles de manière rapide et totalement non invasive.
92% de spécificité
Cette métrique étudie la précision des cas négatifs identifiés par le test. Le résultat négatif du test ColoAlert est vraiment fiable.
3 ans de couverture
La vitesse à laquelle une éventuelle masse tumorale se développe varie en fonction de plusieurs facteurs, comme l'âge, mais le résultat négatif du test ColoAlert vous permet d'attendre jusqu'à 3 ans avant de répéter le processus de dépistage.
Dante Labs World
ColoAlert | Cancer Screening
Share